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Abstract: 8 
Abnormal platelet activity can lead to either bleeding tendencies or inappropriate thrombus 9 
formation. This can occur secondary to a wide variety of disease processes, with a range of clinical 10 
consequences and severity. This article will discuss the pathophysiology of platelet function 11 
abnormalities and consider a logical diagnostic approach in canine and feline patients applicable 12 
to veterinary practice. The recent advances in platelet function testing will then be discussed, both 13 
with regards to detection of platelet dysfunction but also tailoring of pharmacological 14 
manipulation. Although many of these tests are still confined to the research or academia setting, 15 
remote techniques for indirectly assessing platelet function are starting to become available. 16 
Although we still require further research to develop guidelines for the use of these tests in clinical 17 
decision making, the recent advances in this field are an exciting step forward in being able to 18 
detect and manage platelet dysfunction in both primary care and referral level practice.  19 
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Introduction: 24 
Platelets play a vital role in the body’s response to vascular injury and clot formation, known as 25 
haemostasis. For the purposes of clinical and laboratory assessment, the ‘classical model’ of 26 
haemostasis is most applicable. This identifies ‘primary haemostasis’ as the interaction between 27 
platelets, von Willebrand factor (vWF) and subendothelial collagen that results in the formation of 28 
a platelet plug. This plug provides a surface for the assembly of coagulation proteins required for 29 
fibrin formation, known as ‘secondary haemostasis’ (McMichael 2005; Christopherson et al. 2012; 30 
Wei et al. 2009). More recently, the ‘cell based model’ of haemostasis has been developed and 31 
better reflects in vivo coagulation and therefore true bleeding tendency. This model emphasises 32 
the importance of tissue factor bearing cells in initiating coagulation, but also the requirement for 33 
mass platelet activation which provides the negatively charged procoagulant surface required for 34 
massive thrombin production (Smith 2009). In both models, depending on the balance between 35 
platelet stimulation or inhibition, abnormalities in platelet function can either result in 36 
haemorrhagic or thrombotic disorders (McMichael 2005). 37 
With an increase in our current understanding of normal platelet activity has come the development 38 
of a plethora of new diagnostic tests that can better localise abnormalities in platelet function. This 39 
review article aims to summarise the clinically relevant aspects of platelet anatomy and physiology 40 
and identify the potential sources of altered canine and feline platelet function. The investigation 41 
of platelet disorders, with reference to both well-established and new tests of platelet function, will 42 
then also be discussed.   43 
 44 
Normal platelet anatomy and physiology:  45 
Mammalian platelets are anucleate, cytoplasmic fragments that are liberated from megakaryocyte 46 
precursors during thrombopoiesis. The time taken for megakaryocyte maturation and release of 47 
platelets is approximately 3-5 days. Platelet lifespan in laboratory dogs has been reported at 6.0 48 
+/- 1.1 days (van der Meer 2010). No published data is available in cats. Platelet size varies both 49 
inter and intra species, with cats generally having smaller platelets (Sullivan et al. 1993) but with 50 
variation also existing between dog breeds (Lawrence 2013). Most notable is the syndrome of 51 
macrothrombocytopenia in Cavalier King Charles Spaniels (CKCS) and Akitas and the relative 52 
thrombocytopenia in greyhounds (Pederson et al. 2002; Hayakawa 2016; Santoro 2007). These do 53 
not result in a bleeding tendency as an effective total platelet mass is maintained.  54 
 55 
Platelets have several key anatomical characteristics. These are depicted in figure 1.  56 
- Phospholipid membrane with high density of regulated, adhesive receptors (see table 1). 57 
- Cytoskeleton consisting of abundant contractile proteins (e.g. actin and myosin) to allow 58 
shape change. 59 
- A dense tubular system which can sequester or release calcium.  60 
- Secretory granules that allow response to a variety of external stimuli: 61 
o Alpha granules: release adhesive proteins, such as fibrinogen and P-selectin; 62 
prothrombotic factors, such as factor V and XI and growth factors to facilitate 63 
vascular healing.  64 
o Electron dense granules: release platelet agonists required for mass platelet 65 
activation, including adenosine diphosphate (ADP), epinephrine, serotonin, 66 
histamine and calcium. (Sanford et al. 1981; Jerk and Kehrel 2005). 67 
 68 
Primary haemostasis relies on the synergistic activity of multiple receptor interactions to generate 69 
a stable aggregation of platelets, called a platelet plug. The three key stages of primary haemostasis 70 
are platelet adhesion, activation and aggregation and are discussed below. These stages occur 71 
concurrently, with the aim being to generate sufficient platelet aggregation to restore vascular 72 
integrity. Abnormalities associated with any of these stages can result in platelet type bleeding or 73 
thrombosis (McMichael 2005; Wei et al. 2009). The interested reader is directed to a review of 74 
platelet signalling for a more in-depth discussion on this topic (Goggs and Poole 2012). 75 
 76 
Adhesion: 77 
In health, haemostasis is only triggered by injury to a vessel wall. Vascular injury exposes 78 
subendothelial matrix proteins, primarily collagen, to which platelets can bind. Initial tethering is 79 
primarily mediated by direct collagen binding using the GPVI receptor or indirectly via the GP1b-80 
IX-V receptor via von Willebrand’s factor (vWF). The latter has increased relevance at sites of 81 
high blood velocity in the arterial circulation, where the friction (or ‘shear stress’) makes direct 82 
platelet binding difficult. Both of these interactions are short lasting. However, they also stimulate 83 
platelet signalling pathways which result in the conversion of integrin receptors to their high 84 
affinity state. This allows more stable adhesion to collagen, either directly via the α2β1 integrin or 85 
indirectly via the αIIbβ3 integrin using vWF (Nieswant 2003; Brass 2010, Auton 2010). These 86 
adhesions are depicted in figure 2.  87 
 88 
Von Willebrand factor is a large glycoprotein which forms polymers called multimers. These exist 89 
in a range of sizes, or ‘molecular weights’. Larger multimers have a greater affinity for platelets. 90 
The vWF glycoproteins are synthesised in endothelial cells or megakaryocytes and can then be 91 
stored in endothelial Weibel-Palade bodies or platelet alpha granules. Dogs have much less vWF 92 
in platelets compared to cats (Waters et al 1989; McCarroll 1998).  93 
Endothelial cells constitutively secrete small multimers into the subendothelial matrix and large 94 
multimers into the plasma (Lopes da Silva and Cutler 2016). Here, vWF circulates with factor 95 
VIII. Effective secondary haemostasis therefore also requires vWF to prevent the premature 96 
degradation of FVIII (Thomas 1996).  97 
Following vascular injury, large vWF multimers are released from endothelial stores. Subsequent 98 
binding to collagen results in a conformational change, exposing the binding site for the GPIb/V/IX 99 
platelet receptor (Sadler 1998; Ruggeri 1999). Large multimers can also spontaneously bind 100 
platelets without collagen binding (Arya 2002). Platelet adhesion and activation releases further 101 
vWF from alpha granules. Release of vWF can also be stimulated by other substances, such as the 102 
thrombin produced during inflammation (McMichael 2005).  103 
Multimer size is regulated by metalloproteases, specifically ‘A disintegrin and metalloproteinase 104 
with a thrombospondin type 1 motif, member 13’ (ADAMTS-13), which is predominantly 105 
produced by endothelial cells. This proteolytic enzyme cleaves large multimers into smaller 106 
multimers, which have reduced platelet binding potential. When vWF multimers bind to platelets, 107 
they also become more susceptible to cleavage by ADAMTS-13, which allows negative feedback 108 
inhibition. In the absence of ADAMTS-13 activity, ultra large multimers can accumulate resulting 109 
in uncontrolled platelet aggregation and thrombi formation (Arya 2002, Dong 2002). Lower levels 110 
of ADAMTS-13 have been reported in people secondary to neoplastic, inflammatory or 111 
autoimmune conditions (Banno et al. 2006). 112 
  113 
Activation and amplification: 114 
Platelet adhesion triggers intracellular signalling pathways. This results in protein modifications 115 
required for successful aggregation such as: 116 
1. Conversion of integrin receptors, most importantly αIIbβ3, to a high affinity state.  117 
2. Membrane ‘flipping’ to expose the phospholipid ‘’phosphatidylserine’’ (PS). This creates 118 
a negatively charged, procoagulant surface for the assembly of coagulation factors and 119 
generation of thrombin (Satta et al. 2010). 120 
3. Contractile protein activity necessary for platelet shape change. This increases surface 121 
binding area and allows fibrin-clot retraction.  122 
4. Release of granular contents (McMichael 2005; Wei et al. 2009; Satta et al. 2010). 123 
Glycoproteins, such as P-selectin, are transferred to the platelet surface during 124 
degranulation and can provide indirect evidence of activation (Moritz et al. 2005). 125 
 126 
To restore vascular integrity, the original stimulus for platelet activation must be amplified and 127 
sustained using platelet agonists. These are found or produced from a variety of sources, including 128 
the subendothelial matrix (e.g. collagen), platelets themselves (e.g. granule contents or products 129 
of membrane breakdown: thromboxane), other cells (e.g. epinephrine) or through activation of the 130 
coagulation cascade (e.g. thrombin). Each agonist acts at a different receptor and has a variable 131 
capacity to stimulate platelet aggregation (Reviakine 2015). Platelet agonists either increase 132 
intracellular calcium to trigger intracellular signalling or inhibit cyclic adenosine monophosphate 133 
(cAMP) which normally maintains platelets in an inactivated state (Decouture 2015).  134 
Calcium release is triggered via activation of the phospholipase C (PLC) pathway. This enzyme 135 
hydrolyses the platelet phospholipid membrane, generating secondary messengers. These 136 
messengers can induce intracellular release of calcium and activate other enzymes required for 137 
platelet function (Wei et al. 2009, Brass 2010; Reviakine 2015). 138 
The phospholipase A2 (PLA2) pathway is activated indirectly by the PLC pathway and by initial 139 
platelet aggregation. This pathway results in the breakdown of phospholipids to arachiodonic acid 140 
which are converted to thromboxane A2 (TXA2) by cyclooxygenase (COX) enzymes. 141 
Thromboxane A2 is a potent platelet agonist, allowing both autocrine and paracrine signalling. This 142 
pathway can be blocked via inhibitors of COX enzymes (Floyd and Ferro 2013; Reviakine 2015). 143 
Some of these intracellular signalling pathways are illustrated in figure 3. 144 
 145 
Aggregation: 146 
Aggregation of platelets refers to the adhesion of activated platelets to each other using receptor 147 
bound fibrinogen as a bridge. The αIIbβ3 integrin receptor can also bind vWF at sites of high shear 148 
stress. Soluble fibrinogen is found free in the plasma but cannot bind to platelets until they have 149 
been activated. Ongoing action of platelet agonists is therefore required to provide sufficient 150 
aggregation (McMichael 2005; Sangkuhi 2011).   151 
 152 
Inhibition of primary haemostasis: 153 
Platelet aggregation must also overcome several inhibitory mechanisms: 154 
1. Endothelial cells release prostacyclins and adenosine diphosphatase (ADPases). These 155 
either inhibit TXA2 production via the PLA2 pathway or activate cAMP pathways to inhibit 156 
platelet activation (Gale 2011). 157 
2. A layer of negatively charged glycosaminoglycans (GAGs) and proteoglycans, called the 158 
‘glycocalyx’, lines intact vessels and inhibits thrombin formation. The glycocalyx also 159 
releases nitric oxide (NO) at sites of high blood velocity, which inhibits aggregation (van 160 
Hinsbergh 2011; Ralph and Brainard 2014).  161 
 162 
Abnormalities of platelet function resulting in haemorrhage: 163 
Haemorrhage can occur secondary to quantitative and/or qualitative disorders of platelets, vWF or 164 
vasculopathies.  ‘Platelet-type bleeding’, which manifests as ecchymoses and/or petechiae and 165 
intraoperative bleeding, can generally be differentiated from disorders of secondary haemostasis, 166 
in which intra-cavitary bleeding, haematomas and haemarthosis are more common. Mucosal 167 
bleeding (which can be clinically silent or present as urinary or gastrointestinal bleeding) can be 168 
seen with either primary or secondary haemostatic disorders (Gale 2011; Jandrey 2012; Jandrey 169 
2014).  170 
Low numbers of platelets (thrombocytopenia) is the most common cause of platelet type bleeding 171 
and should always be excluded prior to further investigation of platelet function. A platelet count 172 
of 150 x 109/L is the generally accepted lower reference limit (Jain 1986). However, it is not well 173 
understood what severity of thrombocytopenia leads to spontaneous haemorrhage. Platelet counts 174 
less than 30 x 109/L have been associated with spontaneous haemorrhage in dogs with idiopathic 175 
thrombocytopenia (Williams and Maggio-Price 1984) but concurrent platelet or endothelial 176 
dysfunction can result in bleeding at higher platelet counts (Torrent 2005; Ferkau 2013). 177 
Thrombocytopenia will not be covered further in this article as it is well described elsewhere 178 
(Johnstone et al. 1988; O’Marra et al. 2011; Nakamura et al. 2012).  179 
 180 
Qualitative platelet disorders, known as thrombocytopathias, are rare compared to 181 
thrombocytopenia. They are classified as either congenital or acquired and the underlying defect 182 
can generally be categorised as a defect in: 183 
- Adhesion and signalling 184 
- Platelet aggregation 185 
- Prevention of agonist activation or a defect of secondary signalling  186 
- Deficiency of platelet agonists normally stored within the platelet granules (storage pool 187 
deficiencies) (Choi et al. 2014; Paniccia et al. 2015)  188 
 189 
Congenital thrombocytopathias 190 
Inherited platelet disorders are classified as either ‘extrinsic’, in which platelets or the vasculature 191 
lack a functional protein, or ‘intrinsic’ disorders, which are those inherent to the platelet. Some of 192 
the best characterised inherited defects of primary haemostasis are summarised in table 2. The 193 
reader is referred to other sources for more detail (Jandrey 2014, Callan and Catalfamo 2017). 194 
 195 
Acquired thrombopathia: 196 
Acquired disorders of primary haemostasis are typically more heterogeneous in their 197 
pathophysiology and are therefore more difficult to characterise. A variety of conditions have been 198 
reported, with the most well documented summarised in table 3.  199 
Pharmacological manipulation of platelet function can also be used to cause platelet dysfunction 200 
and therefore reduce the risk of thrombus formation. These pharmacotherapies can be categorised 201 
as: ADP receptor antagonists, thromboxane inhibitors and the newer αIIbβ3 integrin receptor 202 
antagonists. Their mechanisms and duration of action are summarised in table 4 and more in depth 203 
information is available in a couple of review articles (Lunsford and Mackin 2007, Thomason et 204 
al., 2016). The interested reader is also referred to a recent consensus statement which summarises 205 
the indications for antithrombotic medication using the current evidence available (Goggs et al. 206 
2018).  207 
Multiple studies have demonstrated the inhibitory effects of aspirin and clopidogrel on platelet 208 
function in healthy dogs (Blois 2010; Brainard 2010; Sharpe 2010; Dudley 2013; Haines 2016, 209 
Saati 2017) and cats, including those with subclinical feline cardiomyopathies (Hogan et al. 2004, 210 
Hamel-Jolette et al. 2009; Teuber and Mischke 2016; den Toom et al 2016).  211 
However, as in people, some dogs and cats have been noted to be poor responders to anti-platelet 212 
medication and are considered ‘resistant’ (also known as ‘high on-treatment platelet reactivity’ 213 
[HTPR]). Aspirin ‘resistance’ in dogs has a reported incidence ranging from 19% to 56% (Dudley 214 
et al., 2013; Haines et al., 2016). There are no published incidences of drug resistance in cats. 215 
However, high interindividual variability in clopidogrel plasma levels has been reported, although 216 
this was considered mostly secondary to differences in metabolism  (Lee 2018).  The results of the 217 
FAT CAT trial (Hogan et al. 2015) did however suggest that clopidogrel is superior when 218 
compared to aspirin in reducing the risk of recurrent aortic thromboembolism.  219 
Individual response to platelet inhibitors can be monitored using platelet function tests or by 220 
measuring markers of platelet activation. However an understanding of the clinical limitation of 221 
each test is required as there is a possibility that reduced platelet activity may not be detected or 222 
reduced activity may not correspond to reduced risk of thrombosis.  223 
The effects of non-steroidal anti-inflammatory drugs (NSAIDs) on in vitro platelet aggregation are 224 
variable (Gaál et al. 2007; Blois 2010; Mullins 2012). One in vivo study demonstrated reduced 225 
platelet aggregation but no increase in buccal mucosal bleeding time (BMBT) in dogs which 226 
received pre-operative ketoprofen prior to ovariohysterectomy (Lemke 2002). A study in cats also 227 
documented no decrease in aggregation following 14 days of meloxicam (Cathcart 2012). Data for 228 
other NSAIDs is lacking and their peri-operative use in patients, especially those with concurrent 229 
primary haemostatic defects, should be carefully considered. Specific guidelines for the peri-230 
operative use of anti-platelet medication is discussed in detail in the previously mentioned 231 
consensus statement and depends on the risk of thrombosis and the type of procedure (Goggs et 232 
al. 2018).  233 
 234 
Intravenous fluid therapy is also known to cause platelet dysfunction. Some canine studies have 235 
suggested that only hypertonic saline, and not hydroxyl starches (HES) (specifically 130/0.4), 236 
result in statistically significant changes to platelet function beyond that associated with 237 
haemodilution alone (Wurlod et al 2015; McBride et al. 2016).  An in vitro study in healthy dogs 238 
also reported evidence of platelet dysfunction associated with anaemia secondary to haemodilution 239 
but the clinical significance of this was questioned (Clancey 2009). A more recent study 240 
investigating resuscitation fluids in a canine haemorrhagic shock model suggested that 20ml/kg of 241 
4% succinylated gelatin was associated with reduced platelet function compared to 20ml/kg fresh 242 
whole blood or 6% HES (130/0.4) or 80ml/kg crystalloids. Additional significant global 243 
coagulation abnormalities were noted in the HES group. Shock alone was associated with a mild 244 
increase in platelet function suggestive of hypercoaguability (Claus 2018). In a feline study, HES 245 
reduced coagulation to a greater degree than a balanced crystalloids solution alone, but platelet 246 
function was not assessed specifically (Albrecht 2016). Mannitol has also been shown to impair 247 
platelet aggregation but not at clinically relevant dilutions (Adamik 2015; Yosava 2017). In 248 
summary, there is still insufficient data to conclude whether various intravenous fluids will cause 249 
clinically significant abnormalities in platelet function. However, where resuscitation can be 250 
achieved with crystalloid therapy alone, the authors would consider this a safer option.  251 
 252 
Von Willebrand Disease (vWD): 253 
Although not strictly a disorder of platelet function, qualitative or quantitative defects in vWF are 254 
the most commonly recognised congenital bleeding disorders in dogs. Patients with vWD can 255 
present with similar clinical signs to platelet function disorders, although generally mucosal 256 
bleeding or excessive bleeding following trauma or surgery are more common (Jandrey 2014). 257 
Since vWF acts as a carrier for factor VIII, prolongation of activated partial thromboplastin time 258 
(APTT) may concurrently occur (Thomas 1996). 259 
Von Willebrand disease is an inherited, autosomal recessive genetic mutation. Three forms of 260 
vWD (types 1-3) are well recognised in dogs and are characterised based on the concentration and 261 
multimeric size of plasma vWF, as well as bleeding severity (Brooks 1999). Dogs with type 1 262 
disease have variable bleeding tendencies depending on the variable expression of the abnormal 263 
gene  (Thomas 1996; Venta et al. 2000). Furthermore, although severe bleeding would be expected 264 
in dogs with type 3 disease, there are also reports of dogs presenting with mild mucosal bleeding 265 
(Pathak 2014; Scuderi 2015). The different types of vWD are summarised in table 5.  266 
In cats, there have been only 2 reported cases of vWD, both of which were considered type 3 267 
(French et al. 1987; Bebar et al. 2014).. Though extremely rare, vWD should therefore still be 268 
considered in cats with clinical signs of primary haemostatic dysfunction. 269 
Acquired von Willebrand syndrome (AVWS) occurs when normal vWF is produced but 270 
concurrent disease results in increased clearance or its inhibition. In dogs, AVWS has been 271 
reported in conjunction with hypothyroidism (Avgeris 1990). Transient AVWS has also been 272 
reported after intravenous colloid administration (Gauthier et al, 2015), secondary to uraemia with 273 
acute kidney injury (McBride 2017) and possibly in association with Angiostrongylus vasorum 274 
infection (Whitley et al. 2005; Hausmann et al. 2016).  275 
Diagnosis of type I and type III vWD is made by measuring low (type I) or minimal (type III) vWF 276 
antigen concentration s(vWF:Ag), (Brooks 1999). Dogs with type II vWD may have  normal 277 
vWF:Ag, however lack large vWF multimers resulting in decreased collagen binding and clinical 278 
signs of primary haemostatic dysfunction (Thomas 1996; Favaloro 2010). Type II vWD is 279 
diagnosed by measuring vWF collagen binding activity (vWF:CBA) or vWF multimeric pattern,  280 
neither of are commercially available to the authors’ knowledge. A summary of the diagnostic 281 
tests available for vWD are given in table 6. Various factors may interfere with these diagnostic 282 
tests (systemic illness and surgery can affect vWF:Ag for example) (Favaloro 2010), therefore 283 
diagnosis of congenital vWD should ideally be made with DNA genetic testing, which  is available 284 
for certain breeds (see table 6).  285 
 286 
Abnormalities of platelet function resulting in inappropriate thrombosis: 287 
Hypercoagulability, or thrombophilia, refers to inappropriate thrombus formation. Virchow’s triad 288 
describes the three broad categories involved in pathological thrombus formation, all of which 289 
may impact platelet function. These include endothelial dysfunction, hypercoagulability and blood 290 
stasis (Ogedegbe 2002; Gale 2011; Wolberg 2012).  291 
 292 
Endothelial dysfunction: 293 
Endothelial dysfunction secondary to inflammation can result in endothelial cell activation and 294 
direct platelet adhesion. It can also disturb production of platelet inhibitors such as prostacyclins 295 
and nitric oxide (NO). Endothelial cell activation can also result in increased secretion of large 296 
vWF multimers and concurrent decrease or absence of ADAMTS-13 (Vischer 2006; Luo et al. 297 
2012).  298 
 299 
Hypercoagulable states:  300 
Inflammatory cytokines can trigger the coagulation cascade, resulting in thrombin production and 301 
platelet activation without adhesion (Esmon 2005). These platelets may also exhibit exaggerated 302 
aggregation in response to a normal stimulus. Activated platelets also provide a procoagulant 303 
membrane and release agonists to further perpetuate aggregation (Brass 2010; Stokes and Granger 304 
2012).  305 
 306 
Blood stasis  307 
Areas of blood stasis are thought to result in hypoxia. Hypoxia is thought to upregulate P-selectin, 308 
which recruits inflammatory leukocytes. These then act as a source of thrombin generation and 309 
further platelet activation (Michiels et al. 2000).  310 
 311 
Clinical signs of thromboembolic disease 312 
Clinical signs are related to either a consumptive coagulopathy with microvascular thrombosis or 313 
thromboembolic (TE) disease. Consumptive coagulopathy is generally associated with signs of 314 
platelet-type bleeding, whereas the site of TE disease will dictate the clinical signs (see table 7) 315 
(Ralph and Brainard et al. 2014; Paniccia et al. 2015). Although these signs may be marked, it can 316 
still be difficult to document an underlying thrombus and advanced imaging may be required 317 
(Goggs et al. 2014).   318 
There are no inherited disorders of thrombophilia reported in veterinary species. Therefore, if 319 
clinical signs of thromboembolic disease are present, diagnostic workup for an underlying disease 320 
process is warranted. It is also important to consider prophylactic therapy in patients with disease 321 
processes known to be predisposed to thromboembolic disease. Disease processes resulting in 322 
either overt thromboembolic disease or microvascular thrombosis are summarised  in table 8. 323 
Although there is evidence of global hypercoagulability with thromboembolic diseases in 324 
veterinary medicine, evidence of increased platelet function is currently limited. 325 
 326 
Diagnostic approach to disorders of platelet function: Haemorrhage  327 
Once clinical evidence of primary haemostatic dysfunction is suspected (petechiae, ecchymosis, 328 
mucosal haemorrhage, bleeding after venepuncture), a diagnostic workup is indicated to 329 
differentiate the different causes of primary haemostatic dysfunction. The approach is summarised 330 
in figure 4 and outlined below: 331 
 332 
1. Perform a Complete Blood Count (CBC) and blood smear assessment (see Figure 5):  333 
A CBC is required to exclude anaemia and thrombocytopenia prior to platelet function testing. 334 
True platelet number and size should also be assessed with a good quality, stained blood smear as 335 
automated blood cell counters may report pseudothrombocytopenia. In cats this usually occurs 336 
because of platelet clumping. There is also considerable overlap between erythrocyte and platelet 337 
volumes, resulting in misclassification by impedance analysers (Wang and Brainard 2014).  338 
 339 
2. Perform prothrombin time (PT) / Activated partial thromboplastin time (APTT): 340 
Prothrombin time and APTT assess the in vitro intrinsic and extrinsic pathways of the cascade 341 
model of secondary haemostasis. This can be particularly useful when physical examination 342 
suggests either primary or secondary haemostatic defects e.g. mucosal bleeding. 343 
 344 
3. Perform buccal mucosal bleeding time (BMBT) [see figure 8): 345 
BMBT is indicated in patients with evidence of bleeding but normal platelet count and PT/APTT. 346 
A specific BMBT lancet device must be used. Reference ranges are device specific but are 347 
generally considered to be less than 4 minutes in dogs and less than 2 minutes in cats. Anaesthesia 348 
and sedation can mildly prolong the BMBT (Sato et al., 2000; Alatsaz et al., 2014).  In a patient 349 
where anaemia and thrombocytopenia are excluded and PT / APTT are normal, a prolonged BMBT 350 
may reflect thrombocytopathia, vWD or more rarely, a vessel wall disorder. It is important to 351 
understand the limitations of the BMBT, as it is highly subjective and prone to significant  inter- 352 
and intraobserver variability (Sato et al 2000; Alatzas et al. 2013). Results should therefore always 353 
be interpreted with caution and verified with more specific testing. A BMBT incision is superficial, 354 
such as to only stimulate platelet plug formation, and therefore is not recommended as a predictor 355 
of surgical haemorrhage.  356 
 357 
4. Von Willebrand Factor Antigen 358 
If the BMBT is prolonged,  the vWF: Ag assay is indicated to differentiate type I and type III vWD 359 
from thrombocytopathia. As mentioned earlier, vWF: Ag cannot diagnose type II vWD as vWF 360 
antigen concentration can be normal. A vWF: Ag assay should also be considered in any patient 361 
with clinical signs of platelet type bleeding with normal platelet count and BMBT, due to the 362 
limitations of BMBT.  363 
 364 
5. Additional screening for infectious disease: 365 
If platelet dysfunction is suspected based on the above diagnostic procedures, infectious disease 366 
screening is also warranted in animals living in, or having a travel history to, an area where 367 
organisms which affect platelet function are endemic.  A common infectious disease which can 368 
cause coagulopathies, including platelet dysfunction, is Angiostrongylus vasorum. A rapid in-369 
house antigen test has high sensitivity and specificity (94% and 95%) (Schnyder 2011), however 370 
a recent study suggests that quantitative PCR of bronchoalveolar lavage may actually have much 371 
better sensitivity (Canonne 2018). Leptospirosis can also cause platelet dysfunction and diagnostic 372 
testing should be based on clinical suspicion.  373 
 374 
6. Genetic testing:  375 
If platelet dysfunction or vWD is suspected in a breed predisposed to congenital platelet function 376 
disorders (table 2) or vWD (table 5), genetic testing can be considered. DNA testing for congenital 377 
defects can be performed on an EDTA sample, or buccal swab.  378 
 379 
7. Platelet function testing:  380 
In patients with platelet type bleeding in which platelet count and vWF: Ag is normal, platelet 381 
function tests (see below) may be indicated. Most of these tests are limited to academic institutes  382 
at the time of this publication.  383 
 384 
Diagnostic approach to disorders of platelet function: Thrombosis  385 
For patients presenting with clinical signs which may be attributable to thromboembolic disease, 386 
a thorough minimum database including CBC with blood smear examination, biochemistry and 387 
urinalysis (including urinary protein: creatinine ratio) is indicated. D-dimers (which are a fibrin 388 
degradation product), can be measured by some in-house analysers and external laboratories. A 389 
low D-dimer concentration has good sensitivity for hypercoaguability but limited ability to specify 390 
the underlying cause (Nelson and Andreason 2003; Dewhurst et al. 2008; Epstein et al 2013). 391 
Prothrombin time and PTT values below the reference range may also indicate hypercoagulability 392 
(Song et al. 2016). Diagnostic imaging may be utilised to both document the presence of a 393 
thrombus (Table 7) and also to investigate for underlying diseases which may lead to thrombosis 394 
(Table 8). Echocardiography may also be indicated if underlying cardiac disease is suspected. If 395 
thrombosis is suspected or detected, platelet function testing can be beneficial in determining if 396 
increased platelet activity is contributing to thrombus formation (Song et al. 2016).  397 
 398 
Blood Sampling: 399 
When collecting a blood sample for assessment of platelet number or function, atraumatic 400 
venepuncture is required to minimise platelet activation and aggregation. For platelet function 401 
testing, the blood sample should be collected with a butterfly catheter attached to an anticoagulated 402 
vacutainer. The appropriate anticoagulant is determined by the test to be performed. The first 403 
sample must be discarded due to risk of platelet activation upon initial venepuncture. Tubes should 404 
be gently inverted and rotated to mix blood and anticoagulant. Most samples must be processed 405 
within two hours of sample collection. If unexpected results are obtained at any stage, then new 406 
sample collection and repeat analysis should be performed. 407 
 408 
Specific tests of platelet function: 409 
Tests of platelet function can be used to diagnose both increased and decreased platelet function. 410 
Although platelet function involves many in vivo mechanisms, these in vitro tests can still provide 411 
important clinical information (Christopherson 2012; Choi et al. 2014). One of the main limitations 412 
of the majority of platelet function tests is that immediate sample processing is required for 413 
accurate results. Many of the tests discussed below are commonly used as bedside point of care 414 
instruments in human hospitals, however at the time of this publication, their availability in 415 
veterinary practice is limited to referral institutes.    416 
 417 
Assessment of platelet adhesion under shear stress 418 
Aperture closure instruments: E.g. Platelet function analyser (PFA) 100 or 200 419 
- The PFA test involves aspirating a citrated whole blood sample through a capillary tube 420 
(to generate shear stress) and then an aperture cut in a biologically active membrane. The 421 
membrane is coated in a platelet agonist. The aspirated sample, once activated by shear 422 
stress and exposure to an agonist, forms a platelet plug over the aperture. The time from 423 
aspiration of the sample to closure of the aperture by a platelet plug is measured as the 424 
closure time (CT) (Kratzer 1985; Harrison 2009).  425 
- The generation of shear stress means the PFA is the only test able to detect abnormalities 426 
of platelet adhesion.  427 
- Three cartridges exist containing different agonists: 428 
o Collagen and ADP (CADP) cartridge  429 
o Collagen and epinephrine (CEPI) cartridge to assess response to aspirin  430 
o Innovance P2Y cartridge measures P2Y12 blockade and response to clopidogrel.  431 
- The PFA-100 has been shown to detect the anti-platelet effects of aspirin, clopidogrel and 432 
NSAIDs in both healthy dogs and cats. As such, it may have clinical utility for monitoring 433 
response to treatment. However, it is also suggested that, compared to optical 434 
aggregometry, the PFA is less reliable in determining drug responsiveness and can 435 
markedly overestimate the degree of aspirin resistance (Gaal 2007; Dudley 2013; Haines 436 
2016; Ho et al. 2016; Saati et al. 2017, McLewee 2018).  437 
- The PFA 100 and 200 have also been used to investigate platelet function in dogs with 438 
valvular disease and cats with cardiomyopathy (Jandrey 2008; Clancey 2009; Moesguaard 439 
2009), as well as dogs with chronic kidney disease and endotoxaemia (Dudley 2017; 440 
Yilmaz 2005). The PFA has also been used to diagnose Scott syndrome (Brooks 2009). In 441 
people, the PFA is used as a screening test for vWD (Ardillon 2015). One study reported 442 
increased CTs in 2 dogs with vWD that responded to DDAVP treatment (Burgess 2009).  443 
 444 
Platelet aggregation  445 
Light transmission aggregometry (LTA): 446 
- Platelet rich plasma processed from a citrated sample is added to platelet agonists including 447 
ADP, thrombin and collagen separately. As platelet aggregates precipitate out, increased 448 
light transmission is detected by photometry creating a curvilinear graph demonstrating 449 
platelet function.  This is considered the gold standard method. However, the requirement 450 
to produce PRP makes it impractical for bed-side testing (Hvar and Favalora 2016).  451 
- Various underlying diseases have been investigated using LTA. One study in dogs showed 452 
variable aggregation in chronic kidney disease; increased aggregation in lymphoma 453 
Cushing’s and diabetes mellitus; and decreased aggregation with ketoprofen but not 454 
carprofen administration (Halmay 2008). More recently LTA has been used alongside the 455 
PFA to investigate the optimum dose of aspirin in dogs (McLewee et al. 2018). 456 
 457 
Electrical impedance platelet aggregometry: E.g. Multiplate® 458 
- Heparinised blood is added to platelet agonists including ADP, arachidonic acid and 459 
collagen. This induces platelet aggregates to form on two electrodes. Increased electrical 460 
resistance is detected between the two electrodes which creates a curvilinear graph 461 
(Kalbanter 2010).  462 
- In healthy dogs, Multiplate® analysis was able to detect reduced platelet aggregation 463 
following both aspirin and clopidogrel therapy and as such may have clinical utility for 464 
monitoring response to therapy (Saati et al. 2017). In cats, normal variability of platelet 465 
function and inability to detect clinically relevant changes following anti-platelet therapy 466 
currently limits the use of Multiplate analysis, although future studies may further optimise 467 
its use in this species (Ho et al. 2015; Ho et al. 2016). 468 
- The Multiplate has also been used to detect reduced platelet aggregation induced in vitro 469 
by the addition of lipopolysaccharide to replicate sepsis (Ferkau et al. 2013, Li and Chan 470 
2016).  471 
- This test should be run within 4 hours of sampling.  472 
 473 
Changes in platelet count: E.g. Plateletworks – an impedance based counter 474 
- Automated platelet counts in EDTA whole blood and citrated whole blood are compared 475 
before and after addition of platelet activators, such as collagen and ADP (Brass, 2010; 476 
Jandrey 2012; Choi et al. 2014).  477 
- Although haematology counters are routinely available, the ‘Plateletworks’ analyser is a 478 
specific point of care assay that uses EDTA and citrate tubes implemented with agonist. 479 
This equipment is more  accessible but individual agonist tubes cannot be purchased and 480 
have a relatively short expiry date. Samples should also be analysed within 10 minutes of 481 
collection.  482 
- In healthy dogs, the Plateletworks analyser was able to detect reduced platelet aggregation 483 
following both aspirin and clopidogrel therapy and as such may have clinical utility for 484 
monitoring therapy (Saati et al. 2017).  In cats, normal variability may again limit clinical 485 
application (Ho et al. 2015). However, studies in both healthy cats and those with 486 
asymptomatic hypertrophic cardiomyopathy have documented clinically detectable 487 
reductions in platelet aggregation following clopidogrel treatment (Hamel-Jolette et al. 488 
2009; Bedard 2009; Ho et al. 2016, (den Toom 2016).  489 
 490 
Global Assessment: 491 
Viscoelastic testing: E.g. Thromboelastography (TEG) +/- platelet mapping and 492 
Rotational Thromboelastometry (ROTEM) 493 
- TEG and ROTEM are global coagulation tests. Therefore, although they include platelet 494 
function in the process of clot formation, the presence of contributing factors such as  495 
thrombin and fibrin formation means they are relatively insensitive to abnormalities of 496 
platelet function (Brainard 2010, Brainard 2011). 497 
- A citrated blood sample is added to a small cup (where activators of coagulation may or 498 
may not be added depending on the type of analysis to be performed), in which a pin is 499 
suspended. With TEG, the cup rotates which detects changes in torque of blood as a blood 500 
clot forms in the cup.  ROTEM differs in that the pin rotates instead of the cup. Lack of 501 
shear stress means these tests are not sensitive to defects in adhesion.  502 
- Platelet number and function in addition to fibrin formation are major determinants of 503 
overall clot strength (TEG = maximum amplitude or ROTEM = maximum clot firmness) 504 
(Brainard 2010, Brainard 2011). 505 
- TEG with ‘platelet mapping’ can better assess platelet function, which requires two TEG 506 
machines running concurrently with different activators including heparin, which can 507 
exclude the contribution of thrombin to maximum clot strength. (Croft 2004).  508 
- Platelet mapping has been validated in healthy dogs (Blois 2013) and has been utilised in 509 
studies investigating clopidogrel efficacy (Brainard 2010).  510 
- A novel  parameter, which aims to differentiate the relative contribution of platelets and 511 
clotting proteases to hypercoagulability, has been retrospectively evaluated in dogs with 512 
immune mediated haemolytic anaemia  (Hamzianpour and Chan 2016). 513 
 514 
Tests to assess platelet components and markers of platelet activation: 515 
Flow Cytometry : 516 
- Specific platelet characteristics, such as receptors and granule contents, are labelled with 517 
fluorescent monoclonal antibodies. When passed through a laser beam, conjugated 518 
antibodies emit a specific wavelength of light. This can be performed before or after 519 
stimulation with various agonists, including ADP, collagen, thrombin and epinephrine. 520 
Therefore, although flow cytometry cannot be used to directly assess platelet function, it 521 
can be used to detect the presence or absence of normal components or markers of 522 
activation.  523 
- Flow cytometry has been used to diagnose inherited canine platelet disorders, such as Scott 524 
Syndrome (Brooks 2002) and Glanzmann’s thrombasthenia (Bordreaux 1996). 525 
- Markers of activation (such as P-selectin) have been used to investigate platelet activity in 526 
conditions such as sepsis (Moritz 2005) and in response to antiplatelet treatment (Sharpe 527 
et al. 2010, Dudley et al. 2013).  528 
- Expensive equipment has previously limited clinical application as a bedside test. 529 
However, a recent study has shown that the addition of a fixative to blood samples may 530 
stabilise platelet activation markers for up to 9 days, allowing remote analysis at a central 531 
laboratory (Dunning et al. 2018). General practitioners are able to request test kits from the 532 
company ‘Platelet Solutions’. This requires no specialist equipment and kits are stable for 533 
at least 9 months at ambient temperature. Further information is available at: 534 
http://www.plateletsolutions.co.uk/products-2/platelet-function-testing-kits/.  535 
 536 
Plasma mean platelet component (MPC) concentration: 537 
- When activated platelets degranulate, there is a decrease in density. This can be assessed 538 
using the plasma mean platelet component (MPC) concentration which is derived from the 539 
platelet refractive index. This value can be obtained from some automated haematology 540 
analysers (Macey et al. 1999).  541 
- Increased platelet P-selectin expression and  decreased plasma MPC concentration 542 
corresponding to platelet activation can be seen in dogs with septic and non-septic 543 
inflammatory conditions (Moritz 2005).  544 
Significantly decreased plasma MPC concentrations have been reported in dogs with 545 
IMHA compared to healthy dogs and dogs with other diseases and has been significantly 546 
associated with survival (Zoia et al., 2018).  547 
 548 
Conclusion: 549 
Our ability to diagnose platelet dysfunction is growing. Although many advanced tests of platelet 550 
function are not available in primary care practice, a logical initial work up of these patients can 551 
still be performed. Current logistical restrictions for the wide application of these tests centre 552 
mainly around the cost of equipment and the requirement to analyse fresh blood samples. With 553 
further research, these limitations may be overcome or alternative strategies in assessing platelet 554 
dysfunction, such as remotely analysing markers of activation, may become more practical. This 555 
could results in clinicians in both primary care and referral level practice having the ability to 556 
perform a more in depth diagnostic work up and allow specific tailoring of antiplatelet therapeutics 557 
to patient with thromboembolic disorders.  558 
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Table 1: Summary of key platelet receptors 1038 






Firm adhesion after activation 
GP VI Collagen Platelet 
adhesion 
Initial tethering triggers intra‐
cellular signalling and activation 
of integrins 
GPIb‐IX‐V vWF Platelet 
adhesion 








Allows fibrinogen binding and 
aggregation after activation 
P2Y1 and P2Y12 ADP Platelet 
agonist 
ADP=Weak platelet agonist 
Site of clopidogrel action 
5HT2 Serotonin Platelet 
agonist 
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Table 3: Summary of acquired disorders of platelet function 1044 
Acquired 
disorders 
Reported mechanisms of 
platelet dysfunction 
Evidence in veterinary species and 
relevance 
Anaemia Considered a rheological 
change in vivo, i.e., reduction 
in “near wall excess” 
(Turitto & Weiss 1980) 
Hct < 35 g/L associated with 
hypocoagulability (Clancey et al. 2009a, 
2009b). 
BMBT improves with blood transfusion 
(Brassard et al. 1994).An artificial 
hypercoagulability may be seen with 
thromboelastography in anaemic 
patients (McMichael et al., 2014).  
Uraemia Storage pool deficiencies; 
decreased response to 
agonists; abnormal calcium 
mobilisation; decreased 
TXA2 synthesis and receptor 
deficiencies; effects of 
concurrent anaemia 
(Boccardo et al. 2004) 
Induced uraemia in healthy dogs lead to 
increased BMBT but no clinical 
bleeding (Brassard et al. 1994). Dogs 
with clinical CKD had platelet 
dysfunction but were hypercoagulable 
on global viscoelastic testing (Dudley 
2013). Dogs with AKI had decreased 
aggregation and type II vWD phenotype 
with high vWFAg:CBA which 
correlated with creatinine (McBride 
2017). 
Hepatopathy Storage pool deficiencies 
(Laffi et al. 1992); decreased 
TXA2 synthesis (Laffi et al. 
1987); adhesion receptor 
deficiencies (Ordinas et al. 
1978, Sanchez‐Roig et al. 
1994). 
Dogs with hepatopathies have been 
shown to have reduced platelet 
aggregation (Willis et al. 1989) 
IMT Antibody against fibrinogen 




Haemorrhage does not always correlate 
with degree of thrombocytopenia and 
additional platelet dysfunction may be 
involved Kristensen et al. (1994) 
DIC Decreased response to 
agonists (Li & Chan 2016); 
increased FDPs suggested to 
compete at platelet 
fibrinogen receptors, limiting 
aggregation (Bick 1988; 
Clinical relevance of platelet 
dysfunction not known. 
Acquired 
disorders 
Reported mechanisms of 
platelet dysfunction 
Evidence in veterinary species and 
relevance 
Gouin et al. 1992; de 
Laforcade et al. 2003). 
Monoclonal 
gammopathy 
Coating of platelets with 
monoclonal or polyclonal 
proteins suspected to cause 
reduced aggregation. 
(Glaspy 1992; Varela et al. 
1997). 
Recurrent epistaxis in Ehrlichia-infected 
dog with normal platelet count, 
prolonged BMBT and abnormal 
aggregation (Varela et al. 1997) 
Leptospirosis Circulation of 
inappropriately activated 
platelets. Decreased response 
to platelet agonists. 
Increased vWF‐platelet 
binding (Barthélemy et al. 
2016; Tunjungputri et al. 
2017). 
Haematuria, melena, petechiae and 
epistaxis seen clinically. 
Hypocoagulability, as measured by 
TEG, associated with mortality; 
however, no platelet function test 




(Adamantos et al. 2015; 
Sigrist et al. 2017). Increased 
FDPs suggested to compete 
at platelet fibrinogen 
receptors, limiting 
aggregation (Bick 1988; 
Gouin et al. 1992). 
Spontaneous bleeding reported in one 
third of dogs. Currently no studies 
investigating platelet function 
specifically (Adamantos et al. 2015; 
Sigrist et al. 2017) 
 1045 
  1046 






ADP receptor antagonists 
Clopidogrel Irreversible P2Y12 
inhibitor 
Life time of 
platelet. Normal 
function returns 5 





Ticagrelor Reversible P2Y12 
inhibitor 
Reversible action 
results in shorter 
duration compared 
to clopidogrel 







inhibition of TXA2 
formation via action 
on the COX‐1 
enzyme 
Life time of 
platelet. Normal 
function returns 7 
to 10 days after 
single dose 
Not all dogs show 






of TXA2 formation 
via action primarily 




serum levels and 
half‐life. 
Inhibition of platelet 
function seen at clinical 
doses. No association 
with bleeding tendency 






of TXA2 formation 
via some action on 
the COX‐1 enzyme 
Dependent on 
specific drug, 
serum levels and 
half‐life. 
Clinically relevant 
inhibition of platelet 
aggregation not expected 




Blockage of receptor 
prevents fibrinogen 
and other ECM 
binding 
Unknown Only reported in 




Table 5: Types of von Willebrand’s disease 1050 







1 Doberman, Corgis, 
Airedale Terriers, and 
various others breeds 
Low Full spectrum 
of sizes 
Mild to moderate 
bleeding 
tendency 
2 German Short Haired 
pointer 






3 Dutch kooiker, 
Scottish terrier, 
Shetland sheepdog 
Marked reduction or 
absence of all 
multimers 
N/A Mild to severe 
bleeding 
 1051 
Table 6: Summary of diagnostic options for dogs with suspected von Willebrand’s factor  1052 
Diagnostic test Clinical utility 
Result 
interpretation Comments 







High inter‐ and 
intraobserver variability 




Diagnosis of type I 
and III vWD 
Normal: 70 to 180% 
Borderline: 50 to 
69% 
Abnormal:0 to 49% 
Influenced by a variety 
of other physiological 





CBA relative to 
vWF:Ag 
VWF: CBA in 
normal/type 1 
dogs=50 to 170% 
Type 2 dogs 
typically >2.0 
Not routinely available. 
Genetic testing Detection of 
causative mutation 
Positive or negative Mode of inheritance not 
completely understood 
in Type 1 disease 










not available and 
non‐specific 
Used in humans as a 
screening test for vWD 
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Table 7: Potential sites of thromboembolic disease 1054 





(Johnson et al. 1999). 
Respiratory changes ranging from 






Acute onset neurological signs e.g. 
lateralised motor deficits or seizures. 
MRI 
Occlusions of peripheral or 
central veins (Williams et al. 
2017; Moise 2007 
Ischaemic damage to the limbs: Acute 
onset limb paralysis with cold 
extremities, firm painful muscles, and 
non‐palpable pulse distal to the 
thromboembolism. 
Swelling of the face. 
Ultrasound 
Occlusion of abdominal veins 
(Slauson & Gribble 1971; Shahar 
et al. 1998; Laurenson et al. 
2010; Respess et al. 2012) 
Ischaemic damage to abdominal 
organs (hepatic, splenic, renal and 
mesenteric vessels). 
Acute abdominal pain and signs 
related to specific organ dysfunction 




  1056 
Table 8: Summary of acquired platelet disorders with proposed mechanism 1057 
Acquired disorders 
Reported mechanisms of 
platelet dysfunction in 
people and dogs 
Veterinary evidence and clinical 
relevance 
Systemic Inflammation 
‐ septic and non‐septic, 
e.g. pancreatitis 
Increased thrombin 
formation leads to platelet 
activation; cytokines 
enhance endothelial 
adhesion; EC dysfunction 
decreases NO and 
prostacyclin production 
(Cheng et al. 2011). 
Cytokines shown to increase 
reactivity to thrombin (Peng et al. 
1996); Endotoxin administration or 
SIRS increases P‐selectin 
expression (Yu et al. 2015). 
Clinical relevance is not known 
and there is insufficient data to 
support routine anticoagulation 
(Goggs et al. 2019). 
Glomerulopathies Loss of inhibitors including 
antithrombin III; 
glomerular EC dysfunction 
and reduced NO (Chen 
et al. 2013). 
Incidence of thromboembolism in 
dogs with PLNs reported as high 
as 25%; albumin nor antithrombin 
levels can be used to predict risk of 
thromboembolic disease (Lennon 
et al. 2013). Antithrombotic 
medication is recommended 
(Goggs et al. 2019). 
IMHA Release of intraerythrocytic 
ADP activates platelets; 
free haemoglobin 
scavenges NO (Helms 
et al. 2013). 
Thromboembolism reported in 46 
to 80% of dogs at post mortem 
(Carr et al. 2002); usually 
hypercoagulable but relative 
hypocoagulability as measured by 
global viscoelastic testing is a 
negative prognostic indicator 
(Goggs et al. 2012); 
circulating activated platelets 
shown by presence of P‐selectin or 
low plasma mean platelet 
component (MPC) concentration 
(Weiss & Brazzell 2006, Ridyard 
et al. 2010, Zoia et al. 2018). 
Antithrombotic medication is 




Increased fibrinogen and 
thrombin‐antithrombin 
complexes promote 
aggregation (Kerlin et al. 
Both hypercoagulability (Halmay 
et al., 2008; Park 2013; Rose et al., 
2011; Rose et al., 2013) and 
hypocoagulability (Klose 2011) as 
Acquired disorders 
Reported mechanisms of 
platelet dysfunction in 
people and dogs 
Veterinary evidence and clinical 
relevance 
2004,Klose et al. 2011 , 
Park et al. 2013). 
measured by global viscoelastic 
testing has been reported but these 
studies are not specific for platelet 
function. 
TEG measurement did not 
normalise in well‐controlled dogs, 
therefore increased plasma 
glucocorticoid concentration may 
not be solely responsible (Klose 
et al. 2011, Park et al. 2013). 
Routine antithrombotic medication 
is not recommended unless other 
risk factors for thrombosis are 
present (Goggs et al. 2019). 
Diabetes mellitus Hyperglycaemia activates 
platelets and promotes 
expression of fibrinogen 
receptors, in addition to 
systemic inflammation and 
EC dysfunction (Schneider 
2009). 
Prevalence in dogs has not been 
documented. 
Cardiomyopathy Platelets circulate in an 
activated state likely 
secondary to EC 
dysfunction (Tablin et al. 
2014). 
Prevalence reported at 0.3% 
(Borgeat 2013); platelet function 
testing does not differ between 
healthy and subclinical cats 
(Jandrey et al. 2008); clopidogrel 
and aspirin reduce the likelihood 
of recurrent ATE (Hogan 2015). 
Routine antithrombotic medication 
is recommended in cats, 
particularly those with left atrial 
dilation, spontaneous echocontrast, 
or reduced left atrial appendage 
flow velocity (Goggs et al. 2019). 
Canine cardiac diseases are not 
associated with a high risk for 
development of thrombosis and 
routine anti‐thrombotics are not 
recommended (Goggs et al. 2019). 
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Figure Legends: 1059 
Figure 1. Key anatomical features of platelets 1060 
 1061 
 1062 
Figure 2. Illustration of key receptors mediating platelet adhesion 1063 
 1064 
  1065 
Figure 3. Illustration of intracellular signalling pathways  1066 
 1067 
 1068 





Figure 5. Exclusion of thrombocytopenia as a cause of platelet type bleeding using a blood smear 1074 
 1075 
 1076 
Figure 6. Canine platelet clump (Modified-Wrights stain x 50 magnification) 1077 
 1078 
  1079 
Figure 7. Feline platelet clump (Modified-Wrights stain x100 magnification) 1080 
 1081 
 1082 
Figure 8. Performing a buccal mucosal bleeding time  1083 
 1084 
 1085 
 1086 
